Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 25.2% in December

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totaling 4,111,105 shares, a drop of 25.2% from the December 15th total of 5,496,827 shares. Based on an average trading volume of 1,018,839 shares, the days-to-cover ratio is currently 4.0 days. Currently, 5.8% of the company’s shares are sold short. Currently, 5.8% of the company’s shares are sold short. Based on an average trading volume of 1,018,839 shares, the days-to-cover ratio is currently 4.0 days.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock traded down $0.20 on Friday, reaching $2.96. The stock had a trading volume of 1,197,857 shares, compared to its average volume of 2,462,671. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $3.95. The stock has a market cap of $213.86 million, a P/E ratio of -1.43 and a beta of 1.75. The company has a 50 day simple moving average of $1.68 and a 200 day simple moving average of $1.57.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12. On average, equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the completion of the transaction, the insider owned 6,459,973 shares of the company’s stock, valued at approximately $8,591,764.09. This trade represents a 53.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Group Walters bought 6,459,973 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average price of $1.20 per share, for a total transaction of $7,751,967.60. Following the acquisition, the insider owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. This represents a 91.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Millennium Management LLC grew its position in shares of Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Zentalis Pharmaceuticals by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Zentalis Pharmaceuticals by 4.7% during the second quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock valued at $3,241,000 after buying an additional 124,985 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Zentalis Pharmaceuticals by 117.1% in the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock worth $2,339,000 after buying an additional 835,466 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. grew its stake in Zentalis Pharmaceuticals by 53.7% during the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after acquiring an additional 516,666 shares in the last quarter.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Morgan Stanley reduced their price target on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 12th. Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Leerink Partners restated a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.53.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.